GSK (NYSE:GSK) Releases FY 2024 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.710-1.740 for the period, compared to the consensus estimate of 4.060. The company issued revenue guidance of $40.9 billion-$41.7 billion, compared to the consensus revenue estimate of $41.5 billion.

GSK Trading Up 0.3 %

Shares of GSK stock opened at $36.87 on Friday. The stock has a 50 day simple moving average of $40.66 and a 200 day simple moving average of $41.02. GSK has a 1 year low of $33.67 and a 1 year high of $45.92. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99. The stock has a market cap of $76.41 billion, a P/E ratio of 23.94, a price-to-earnings-growth ratio of 1.23 and a beta of 0.65.

GSK (NYSE:GSK) last released its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. The company had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. GSK had a return on equity of 51.23% and a net margin of 7.97%. On average, research analysts predict that GSK will post 4.08 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.26%. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio is presently 98.70%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on GSK shares. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday. Argus raised GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $50.00.

Insiders Place Their Bets

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the acquisition, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 10.00% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.